* need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. * history of or current hospitalization for covid-19. * history of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry. * personal or family history of long qt syndrome. * history of kidney disease. * history of ischemic or structural heart disease. * history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation * personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. * used drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. * requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. * loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. * participated in a study where co-enrollment was not allowed. * receipt of a sars-cov-2 vaccination prior to study entry. * known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. * more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: * fever (can be subjective) or feeling feverish * cough * shortness of breath or difficulty breathing at rest or with exertion * sore throat * body pain or muscle pain * fatigue * headache * chills * nasal obstruction or congestion * loss of taste or smell * nausea or vomiting * diarrhea

* need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. * history of or current hospitalization for covid-19. * history of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry. * personal or family history of long qt syndrome. * history of kidney disease. * history of ischemic or structural heart disease. * history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation * personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. * used drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. * requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. * loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. * participated in a study where co-enrollment was not allowed. * receipt of a sars-cov-2 vaccination prior to study entry. * known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. * more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: * fever (can be subjective) or feeling feverish * cough * shortness of breath or difficulty breathing at rest or with exertion * sore throat * body pain or muscle pain * fatigue * headache * chills * nasal obstruction or congestion * loss of taste or smell * nausea or vomiting * diarrhea

- need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. - history of or current hospitalization for covid-19. - history of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry. - personal or family history of long qt syndrome. - history of kidney disease. - history of ischemic or structural heart disease. - history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation - personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. - used drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. - requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. - loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. - participated in a study where co-enrollment was not allowed. - receipt of a sars-cov-2 vaccination prior to study entry. - known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. - more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - chills - nasal obstruction or congestion - loss of taste or smell - nausea or vomiting - diarrhea

- need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. - history of or current hospitalization for covid-19. - history of ventricular arrhythmia or use of antiarrhythmics within 30 days prior to entry. - personal or family history of long qt syndrome. - history of kidney disease. - history of ischemic or structural heart disease. - history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation - personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. - used drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. - requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. - loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. - participated in a study where co-enrollment was not allowed. - receipt of a sars-cov-2 vaccination prior to study entry. - known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. - more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - chills - nasal obstruction or congestion - loss of taste or smell - nausea or vomiting - diarrhea

- need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. - history of or current hospitalization for covid-19. - history of ventricular arrhythmia or using antiarrhythmics within the past 30 days. - personal or family history of long qt syndrome. - history of kidney disease. - history of ischemic or structural heart disease. - history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation - personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. - use of drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. - requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. - loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. - participating in a study where co-enrollment is not allowed. - receipt of a sars-cov-2 vaccination prior to study entry. - known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. - more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - chills - nasal obstruction or congestion - loss of taste or smell - nausea or vomiting - diarrhea

- need for hospitalization or immediate medical attention in the clinical opinion of the study investigator. - history of or current hospitalization for covid-19. - history of ventricular arrhythmia or using antiarrhythmics within the past 30 days. - personal or family history of long qt syndrome. - history of kidney disease. - history of ischemic or structural heart disease. - history of hypokalemia or hypomagnesemia or taking potassium supplementation or magnesium supplementation - personal medical history of porphyria, retinopathy, severe hepatic impairment, or glucose-6-phosphate dehydrogenase (g6pd) deficiency. - use of drugs with possible anti-sars-cov-2 activity within 30 days prior to study entry, e.g., remdesivir, lopinavir/ritonavir fixed dose combination, ribavirin, chloroquine, hydroxychloroquine, and azithromycin, or participation in a clinical trial involving any of these drugs whether for treatment or prophylaxis. - requirement or expected requirement for a medication that significantly prolongs qt intervals or increases risk for qt prolongation. - loop diuretics are exceptions to above exclusion criterion but these cannot be used within 30 days prior to study entry. - participating in a study where co-enrollment is not allowed. - receipt of a sars-cov-2 vaccination prior to study entry. - known allergy/sensitivity or any hypersensitivity to components of hcq, azithromycin, or their formulation. - more than 10 days of any of the following symptoms attributed to the sars-cov-2 infection at study entry: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - chills - nasal obstruction or congestion - loss of taste or smell - nausea or vomiting - diarrhea